Skip to main content



) --

Enzon Pharmaceuticals



) hit a new 52-week low Thursday as it is currently trading at $7.38, below its previous 52-week low of $7.42 with 129,976 shares traded as of two p.m. ET. Average volume has been 377,600 shares over the past 30 days.

Enzon has a market cap of $384.6 million and is part of the

health care

sector and


industry. Shares are down 36.7% year to date as of the close of trading on Wednesday.

Enzon Pharmaceuticals, Inc., a biotechnology company, engages in the research and development of therapeutics for cancer patients with unmet medical needs.

  • Practice your ENZN trading strategies and win cash in our stock game.

TheStreet Ratings rates Enzon as a


. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. You can view the full

Enzon Ratings Report


See all

52-week low stocks

or get investment ideas from our

investment research center